LPL PvuII genotype | Niacin (mg/day) Tertile range | Non-MetSyn N (%)a | MetSyn N (%)a | OR (95% CI)b | OR (95% CI)c | |
---|---|---|---|---|---|---|
P1P1/P1P2 | Tertile 1d | ≦14.82 | 26 (20.5%) | 24 (17.1%) | 1.00e | 1.00e |
Tertile 2 | 14.83–17.80 | 21 (16.5%) | 28 (20.0%) | 1.08 (0.58–2.04) | 1.26 (0.65–2.47) | |
Tertile 3 | ≧17.81 | 21 (16.5%) | 29 (20.7%) | 1.07 (0.57–2.02) | 0.71 (0.36–1.41) | |
P2P2 | Tertile 1 | ≦14.82 | 17 (13.4%) | 30 (21.4%) | 2.39 (1.25–4.56) | 2.24 (1.16–4.35) |
Tertile 2 | 14.83–17.80 | 23 (18.1%) | 9 (6.4%) | 0.34 (0.16–0.72) | 0.26 (0.12–0.57) | |
Tertile 3 | ≧17.81 | 19 (15.0%) | 20 (15.0%) | 0.71 (0.36–1.40) | 0.71 (0.46–1.10) | |
P for trend | 0.149 | 0.038 | ||||
Total subject | Tertile 1 | ≦14.82 | 43 (33.9%) | 54 (38.6%) | 1.00e | 1.00e |
Tertile 2 | 14.83–17.80 | 44 (34.6%) | 37 (26.4%) | 0.47 (0.29–0.76) | 0.47 (0.28–0.78) | |
Tertile 3 | ≧17.81 | 40 (31.5%) | 49 (35.0%) | 0.61 (0.38–0.98) | 0.46 (0.28–0.77) | |
P for trend | 0.044 | 0.003 |